West Pharma sees no effect on results from Pfizer's Exubera move

viernes 19 de octubre de 2007 00:35 CEST
 

Oct 18 (Reuters) - West Pharmaceutical Services Inc (WST.N: Cotización) said Pfizer Inc's (PFE.N: Cotización) decision to return marketing rights of inhaled diabetes drug Exubera to Nektar Therapeutics Inc (NKTR.O: Cotización) is not expected to impact its third-quarter results and annual earnings outlook.

West Pharmaceutical sees 2007 earnings, excluding items, of $2.27 to $2.37 per share.

West Pharmaceutical's tech group is one of two companies that produce the Exubera inhalation device for Nektar, which is a partner of Pfizer. (Reporting by Sweta Singh in Bangalore)